A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma

Trial Profile

A Phase 1b/2, Multicenter, Open-label, Dose-escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 May 2017

At a glance

  • Drugs Elotuzumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 24 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 15 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Nov 2016.
    • 15 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top